We observed in the ABCB1high group a significant increase in AML subgroups bearing RUNX1, TP53 and GATA2 mutations, and a decrease in AML patients presenting NPM1 and FLT3-ITD mutations. This evidence concerns the gene TP53 and acute myeloid leukemia.